AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01791803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hypnotherapy
Description: One 90 minute session within 2 weeks of hospital discharge
Study NCT01791803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: free one month supply after hospital discharge
Study NCT03298685 — intervention group
Intervention type: OTHER
Intervention: semi structured interviews for all adolescents and their parent
Description: Before and after transition, individual semi structured interviews will be recorded by one person in the same way in all CF center. And every interview will be transcribed by an other person
Study NCT02778243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: steroids concentrations determination
Study NCT02778243 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: steroids concentrations determination
Study NCT04369989 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01980654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: All subjects will receive 560 mg of Ibrutinib orally.
Study NCT01980654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: All subjects will receive rituximab 375 mg/m2 intravenously
Study NCT04109196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy is an evidence-based treatment for PTSD that will be delivered intensively twice per day over the course of five days.
Study NCT02214433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV Solution
Description: A sterile IV solution of 5% dextrose in water
Study NCT02214433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1450 IV Solution
Description: A white to off-white powder (40 mg Debio 1450 per vial) to be reconstituted and formulated in a sterile IV solution of 5% dextrose in water
Study NCT02214433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet or Capsule
Description: Placebo tablet or capsule, matching Debio 1450 coated tablet or capsule
Study NCT02214433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1450 Tablet
Description: Debio 1450 40 mg coated tablets
Study NCT02214433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1450 Capsule
Description: Debio 1450 40 mg capsules
Study NCT02214433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1450 Oral Solution
Description: Lyophilized Debio 1450 (40 mg per vial) reconstituted in 5% dextrose in water
Study NCT02214433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole 40 mg orally
Study NCT01101477 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TCI titration by different Cet.
Description: Induction:~After topical xylocaine and alfentanil 5μg/kg iv 1 minute before, Cet 2.0μg/ml is started on the TCI pump ('Vial Injectomat TIVA Agilia syringe infusion pump, Fresenius Kabi, France). The sedative level will be accessed by sedation scale OAA/S every 30 seconds till OAA/S ≦3(Responds only to name called loudly). The current Ce will be set as the maintenance Cet.~If desired OAA/S is not achieved after reaching 2.0μg/ml,Cet will be increased every 90 seconds by the regimens be assigned until OAA/S ≦3. The current Ce will be set as the maintenance Cet.~Maintenance:~The Cet will be increased according to the assigned regimens if:~1. Patients become irritant and interfere procedures.~2. Patients open eyes or talk to express uncomfortable.~The Cet will be decreased if:~1. Systolic blood pressure is less than 90mmHg;~2. Mean arterial blood pressure is less than 65mmHg;~3. Oxyhemoglobin saturation is less than 90 %~with any duration.
Study NCT00186862 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Interleukin-2
Description: A genetically modified (retroviral) allogeneic tumor vaccine coupled with the human interleukin-2. Patients were treated with 4 injections of these gene-modified tumor cells. The first two were given at weeks 1 and 2. Patients then had a 2 week rest and the remaining 2 injections were given at weeks 4 and 5. A complete evaluation for evidence of toxicity and response were performed at week 8.~At this week 8 evaluation, if there was no excessive toxicity, progressive disease requiring therapy, and if more transduced cells are available, patients had the option to receive 4 additional injections. These additional injections were separated by 1 month at the higher of the two dosage levels originally received.
Study NCT03774160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Generacion Actual
Description: See description in arm description.
Study NCT03635333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine level (6 or 18 mg)
Study NCT03635333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavor
Description: Flavor of e-juice (tobacco, menthol, strawberry)
Study NCT01969591 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fast-track surgery
Description: Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
Study NCT01969591 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional postoperative surgery
Description: Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
Study NCT00604279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (R092670)
Description: Paliperidone palmitate suspension for intramuscular injection at a dose of 150 milligram equivalent (mg eq.) at baseline, 100 mg eq. on Day 8, flexible dose, either 50 or 100 mg eq on Day 36 and 50, 100, or 150 mg eq.on Day 64 depending on investigator's discretion.
Study NCT00604279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone LAI intramuscular at a dose of 25 mg on Day 8 and Day 22; flexible dose of either 25 or 37.5 mg on Day 36 with same dose on Day 50; and either 25, 37.5, or 50 mg on Day 64 with same dose on Day 78; along with oral risperidone 2 mg tablet on Day 1, flexible doses (1-6 mg/day) for first 28 days; and 1-2 mg/day during Day 36-57 and Day 64-85 if the dose of risperidone LAI was increased on Day 36 and Day 64.
Study NCT02672215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Start to stand
Description: web-based computer-tailored intervention including personalized feedback and tips on how to reduce and/or interrupt workplace sitting
Study NCT02672215 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: generic advice
Description: general, non-tailored web-based generic advice with tips
Study NCT01602523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/formoterol
Description: Budesonide/formoterol Spray inhaler 160/4.5 mcg daily 28 days
Study NCT01602523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhaler once daily 28 days
Study NCT04234425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Informed Yoga
Description: Trauma-Informed Yoga practice held within a high school weight training class
Study NCT01072877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polidocanol injectable foam (PEM)
Description: Injection of Polidocanol injectable foam
Study NCT01072877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Description: Placebo vehicle
Study NCT00003600 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epoetin alfa
Study NCT00003600 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01786174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilenya
Description: 0.5mg Gilenya orally by mouth once daily for approximately 28 days
Study NCT01786174 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5mg placebo (sugar pill) orally by mouth once daily for approximately 28 days
Study NCT01059136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Unique 200mg IV dose of Potassium Canrenoate followed by 25 mg daily oral dose of Spironolactone for 6 months
Study NCT03540953 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Endoscopic injection of Mitomycin C
Description: administration included dilation of the stenotic segment with thermoplastic bougies, followed by the injection of 3mg of Mitomycin C, divided into 4 aliquots of 0.75mg, injected in the four quadrants, at the stenosis level.
Study NCT02041741 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly tips
Description: Participants in this condition receive weekly a more in-depth tip to increase feelings of happiness involving a (doing and experiencing) task
Study NCT02041741 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Tips
Description: Participants in this condition receive daily a set of small tips aimed at increasing happiness
Study NCT02837835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftazidime
Description: 20 mg/kg of body weight followed by 60 mg/kg/day
Study NCT02837835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftazidime
Description: 20 mg/kg over 30 min every 8 h
Study NCT01048567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus acidophilus/rhamnosus
Description: 2 capsules (at least 2 billion cells per capsule) three times daily for duration of antibiotic therapy
Study NCT01048567 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules three times daily for entire duration of antibiotic therapy.
Study NCT03130543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice cereal
Description: Standard formula thickened with rice cereal
Study NCT03130543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enfamil AR
Description: Enfamil AR formula
Study NCT02523053 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatectomy
Description: Surgical removal of all lesions
Study NCT02523053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatectomy
Description: Surgical removal of all lesions
Study NCT02523053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Surgical removal of all lesions and intraoperative controlled release 5-Fluorouracil therapy
Study NCT04721093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation device
Description: In this study, PBM was applied using a machine made to be attached to the subject in the form of a probe. In this clinical trial, a low-intensity irradiation device (Color-DNA-WSF U) from Color seven was used to deliver visible light (610nm± 10nm wavelength, 3.0mW/㎠±20%) irradiation. PBM was applied 5 times a week for 8 weeks, 30 minutes per session.
Study NCT00273767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin beta
Description: 800UI/kg in 60ml of Nacl IV slow 1 to 3 hours before surgery
Study NCT00273767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 60ml of NaCl IV slow
Study NCT02732054 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Hepatitis B vaccine [(CIGB) La Habana, Cuba]
Description: Different HBV vaccine regimen in each group
Study NCT02732054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Hepatitis B vaccine [(CIGB) La Habana, Cuba]
Description: Different HBV vaccine regimen in each group
Study NCT03077360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Description: Lifestyle changes to lose weight or become more fit
Study NCT03736161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A- Tofacitinib
Description: Group A patients will receive Tofacitinib 5mg BD. Patients will be followed up at 1, 3 and 6 months. Patients with inadequate response to Tofacitinib 5 mg BD at the end of 3 months will be put on Tofacitinib 10 mg BD. Primary endpoint for efficacy will be determined by ACR 20 response.
Study NCT03736161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group B- Methotrexate
Description: Group B patients will receive Methotrexate in increasing dose weekly with maximum dose up to 25 mg/week. Patients will be followed up at 1, 3 and 6 months. Patients with inadequate response to highest dose of MTX at the end of 3 months will be put on Tofacitinib 5 mg BD. Primary endpoint for efficacy will be determined by ACR 20 response.
Study NCT03010930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplementation of diet with MSG
Description: Subjects eat normal diet and consume 8 ounces of vegetable broth with added MSG one time per day for 1 month
Study NCT03010930 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No supplementation of diet with MSG
Description: Subjects eat normal diet and consume 8 ounces of low glutamate vegetable broth without MSG (sodium-matched with NaCl) one time per day for 1 month
Study NCT02532153 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine Hydrochloride
Description: Single open-label infusions
Study NCT02151422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing exercise
Description: Patients will be thought 3 different exercises included yoga pranayama, diaphragmatic breathing and pursed lip breathing. Patients will be asked to repeat these exercises at least twice daily for a one month period. Also patients will be thought 4 different exercises which they could use in the event of an asthma exacerbation. Teaching will be supplemented by a breathing exercise brochure and patients will be asked to demonstrate proper technique at initial visit and at the return visit.
Study NCT04179331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurotensin
Description: Neurotensin is an endogenous peptide released from the distal small intestine. It will be administered at three doses (2.5, 5.0 and 7.5pmol/kg/min), each for 1h, in sequence.
Study NCT04179331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Isotonic saline will serve as a placebo.
Study NCT00124852 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: n-3 Fatty Acid Supplementation
Study NCT00124852 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: n-3 Fatty Acid Supplementation
Study NCT01765192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast was supplied in tablets.
Study NCT01765192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast placebo
Description: Roflumilast placebo was supplied in tablets.
Study NCT01765192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast was supplied in tablets.
Study NCT03794908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light therapy A (Bright) via the Re-Timer®
Description: Subjects will conduct light treatment in the mornings at home for one hour using Re-timer®.
Study NCT03794908 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light therapy B (Dim) via the Re-Timer®
Description: Subjects will conduct light treatment in the mornings at home for one hour using Re-timer®.
Study NCT01486771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macugen ® (pegaptanib sodium)
Description: Patients assigned to either IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. The group will then receive an intravitreal injection every 12 weeks.~Patients assigned to IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. After the third injection subjects in this group will receive Selective Laser Photocoagulation at Week 18.~Patients assigned to Panretinal Photocoagulation will act as the control group. Subjects in this group will receive standard Panretinal Photocoagulation using a modified ETDRS protocol.~All intravitreal study injections will consist of 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection.
Study NCT02582125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Study NCT02797353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal Neonatal and Child Health Interventions
Description: Antenatal care, postnatal care, skilled birth attendance, recognition and referral of complicated cases, immunization
Study NCT03520933 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PGT-A
Description: PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
Study NCT03520933 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: niPGT-A
Description: Non-invasive preimplantation genetic test for embryo aneuploidy analyzing the spent culture media where the embryo is incubated up to the time of vitrification. This media contains traces of embryonic cell-free DNA (cfDNA) that can represent the genetic load of the embryo.
Study NCT01364363 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic transplantation
Description: Allogeneic transplantation with matched unrelated donors
Study NCT02366377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Study NCT02366377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02366377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT01315223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung impedence-guided treatment
Description: One hundred fifty patients with CHF will be treated according to common practice and values of lung impedance
Study NCT03459144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verteporfin
Description: Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab(0.05mg) will be given to the participants when necessary（every three months）.
Study NCT03459144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verteporfin and ranibizumab
Description: Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary.
Study NCT02677012 — intervention group
Intervention type: PROCEDURE
Intervention: Autologous Fat Graft
Description: Undergo AFG using the RESOLVE TM technique
Study NCT02677012 — intervention group
Intervention type: PROCEDURE
Intervention: Autologous Fat Graft
Description: Undergo AFG using the Cytori PureGraft TM technique
Study NCT02677012 — intervention group
Intervention type: PROCEDURE
Intervention: Autologous Fat Graft
Description: Undergo AFG using the Coleman technique
Study NCT02677012 — intervention group
Intervention type: PROCEDURE
Intervention: Reconstructive Surgery
Description: Undergo reconstructive surgery
Study NCT00876694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 µg
Description: Indacaterol 300 µg once daily (od) via SDDPI
Study NCT00876694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol 50 µg
Description: Salmeterol 50 µg twice daily (bid) via Diskus®
Study NCT00442065 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aorfix™ Stent Grafts (AAA endovascular procedure)
Description: Endovascular treatment of AAA using the Aorfix™ Stent Graft and Delivery System
Study NCT02839954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-MUC1 CAR-pNK cells
Study NCT00288509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: In this long-term extension study, a dose of 500 units Dysport was administered by intramuscular injection into the clinically indicated neck muscles in a single dosing session in the first treatment cycle. This was the same dose as given in the preceding study NCT00257660 (Y-47-52120-051). Based on individual safety \& efficacy, subjects could then receive up to 3 subsequent injections with doses titrated in 250 unit steps, to a minimum of 250 units and a maximum of 1000 units. Retreatment occurred approximately 12-16 weeks after the previous injection, with the exact timing based on clinical need.
Study NCT01019512 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01019512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01019512 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lymphedema management
Study NCT01019512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lymphedema management
Study NCT00730171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Linaclotide capsules, oral, once daily each morning at least 30 minutes before breakfast for the duration of the study.
Study NCT03516630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: Tablet